# C4X Discovery Holdings plc Final results – Engine running

- Link: https://www.directorstalkinterviews.com/c4x-discovery-holdings-plc-final-results-engine-running/412720065
- Published: 2017-01-06T07:08:15+00:00
- Author: Giles Arbor

**C4X Discovery Holdings plc** (LON:C4XD), an innovative company in the discovery,
rational design and development of small-molecule drugs, has reported its results
for the 12 months to July 31, 2016. During the period the company further enhanced
its drug discovery engine through acquisitions and continued to advance and broaden
its portfolio of proprietary drug discovery programmes. The acquisitions (Adorial’s
innovative target discovery platform technology, Taxonomy3, and Molplex’s pioneering
chemoinformatics and artificial intelligence software platform), combine powerfully
with C4XD’s drug discovery and rational molecule optimisation technology platform,
Conformetrix, to create a state-of-the-art drug discovery engine. We believe this
has the potential to become one of the industry’s most productive drug discovery
engines generating better drug candidates against smarter new targets, substantially
more rapidly and cost-effectively than existing industry approaches. With the strategic
shift away from fee-for-service deals towards building the proprietary drug portfolio
and signing higher-value partnership and out-licensing deals, we believe now is 
a great time to buy into C4XD.

Financials: Total revenues for the year of £0.2m (FY2015: £0.2m) relate to income
from partners generated through collaborative projects. As anticipated the operating
loss of £6.8m increased against the prior year (£3.9m) due to greater R&D spending(
FY16 £5.2m vs FY15 £3.2m) and higher central costs associated with management changes
and increased headcount, a move to different premises, and additional operating 
costs following acquisitions. Our forecasts remain unchanged and with the £5.0m 
fund-raising in September 2016, we expect cash to be approximately £1.5m at year
end (July 31, 2017).

Strategy: Approximately 2/3 of marketed new drugs originated from smaller biotech
companies and almost 70% of the current global industry clinical development pipeline
belongs to emerging companies (not large pharma). In this context, the opportunity
for C4XD to out-license its proprietary drug candidates to larger drug companies
is increasing as demand from large pharma to supplement their pipelines grows. C4XD
continues to build and progress its pipeline programmes in a variety of therapeutic
areas including addiction, diabetes, inflammatory diseases and cancer, among others.
The company intends to further expand the list of target areas to include additional
inflammatory conditions and neurodegenerative diseases and to out-license at least
one asset in the next 12 months.

Zeus Comment: C4X Discovery Holdings plc has important collaborations in place e.
g. with the University of Oxford’s Structural Genomics Consortium (SGC Oxford) and
Evotec, and 8 programmes in a number of high-value therapeutic areas. We believe
it is well placed to deliver on its strategy of running a self-sustaining drug discovery
engine suppling first-and-best-in-class drug candidates for in-licensing to pharma
partners.

Share on:
